These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12882629)

  • 1. 6th International Conference on Alzheimer's Disease and Parkinson's Disease.
    Lahiri DK
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1433-40. PubMed ID: 12882629
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.
    Gozes I
    J Mol Neurosci; 2004; 24(3):333-6. PubMed ID: 15655257
    [No Abstract]   [Full Text] [Related]  

  • 3. Protein degradation in Alzheimer's disease and aging of the brain.
    Tsuji T; Shimohama S
    Prog Mol Subcell Biol; 2002; 29():43-60. PubMed ID: 11908072
    [No Abstract]   [Full Text] [Related]  

  • 4. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
    Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 8th International Conference on Alzheimer's Disease and Related Disorders, July 20-25, 2002, Stockholm, Sweden.
    Kimberly WT; Kovacs DM; Walsh D; Lashuel H; Lemere CA
    Amyloid; 2003 Mar; 10(1):51-61. PubMed ID: 12762144
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycogen synthase kinase-3 beta and tau genes interact in Parkinson's and Alzheimer's diseases.
    García-Gorostiaga I; Sánchez-Juan P; Mateo I; Rodríguez-Rodríguez E; Sánchez-Quintana C; del Olmo SC; Vázquez-Higuera JL; Berciano J; Combarros O; Infante J
    Ann Neurol; 2009 Jun; 65(6):759-61; author reply 761-2. PubMed ID: 19557862
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
    Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL
    FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts, Results, and Perspectives of the Current Alzheimer's Disease Research.
    Marco-Contelles J
    ACS Chem Neurosci; 2019 Mar; 10(3):1127-1128. PubMed ID: 30707547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?
    Kurosinski P; Guggisberg M; Götz J
    Trends Mol Med; 2002 Jan; 8(1):3-5. PubMed ID: 11796255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum series: grappling with the overlap between Alzheimer's and Parkinson's diseases. 9th International Conference on Alzheimer's and Parkinson's Diseases, 11-15 March 2009, Prague,Czech Republic.
    Strobel G
    J Alzheimers Dis; 2009; 18(3):625-40. PubMed ID: 19749400
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial to the Special Issue "Lipidomics and Neurodegenerative Diseases".
    Calvano CD; Losito I; Cataldi T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecules of the brain.
    Levey AI
    Hosp Pract (1995); 2000 Feb; 35(2):41-8, 51-4. PubMed ID: 10689389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical studies of protein misfolding and aggregation in
    Sinnige T; Stroobants K; Dobson CM; Vendruscolo M
    Q Rev Biophys; 2020 Jun; 49():e22. PubMed ID: 32493529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.
    Walsh DM; Selkoe DJ
    Protein Pept Lett; 2004 Jun; 11(3):213-28. PubMed ID: 15182223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease.
    Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D
    Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
    Windisch M; Hutter-Paier B; Rockenstein E; Hashimoto M; Mallory M; Masliah E
    J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer disease therapeutics.
    Irizarry MC; Hyman BT
    J Neuropathol Exp Neurol; 2001 Oct; 60(10):923-8. PubMed ID: 11589422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer's disease.
    Porzoor A; Macreadie IG
    J Alzheimers Dis; 2013; 35(2):217-25. PubMed ID: 23396350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein.
    Lashuel HA; Grillo-Bosch D
    Methods Mol Biol; 2005; 299():19-33. PubMed ID: 15980593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.